InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,430.40
(
0.14%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.51
(
-0.22%
)
Bitcoin
65,245.41
(
0.43%
)
Post# of 252255
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

JJM760

Send PM Follow Ignore
Followers 5
Posts 993
Boards Moderated 0
Alias Born 06/15/2010

JJM760

Re: DewDiligence post# 140738

Tuesday, 04/24/2012 10:31:53 PM

Tuesday, April 24, 2012 10:31:53 PM

Post# of 252255

In 2010, NICE rejected Tasigna, but NVS evidently gave them a better deal this time



Gleevec is going generic, but would it be a smart business decision (and feasible) for Ariad to price Ponatinib lower than Tasigna? Would it make a difference?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up